Drug Trial Radar · NCT07766369
A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
93
Planned (sponsor's estimate)
Start
Aug 12, 2026
Primary completion
Nov 12, 2026
Study completion Nov 12, 2026
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Aug 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to assess potential drug-drug interactions of E2086 when coadministered orally with Itraconazole, Carbamazepine, Midazolam, Dextromethorphan, Bupropion, or Combined Oral Contraceptives in Healthy Participants
Conditions
- Healthy Volunteers
Interventions
E2086Drug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A, area under concentration versus time curve from zero time (predose) to time of last quantifiable concentration AUC(0-t) of E2086 and its Metabolite M1Time frame: Day 1 to Day 4; Day 7 to Day 13
- Part A, area under concentration versus time curve from zero time (predose) to infinite time AUC(0-inf) of E2086 and its Metabolite M1Time frame: Day 1 to Day 4; Day 7 to Day 13
- Part A, maximum observed concentration (Cmax) of E2086 and its Metabolite M1Time frame: Day 1; Day 7
- Part B, AUC(0-t) of midazolam (MDZ)Time frame: Day 1 to Day 4; Day 15 to Day 18
- Part B, AUC(0-t) of dextromethorphan (DEX)Time frame: Day 1 to Day 4; Day 15 to Day 18
- Part B, AUC(0-t) of bupropion (BUP)Time frame: Day 4 to Day 8; Day 18 to Day 22
- Part B, AUC(0-t) of hydroxybupropionTime frame: Day 4 to Day 8; Day 18 to Day 22
- Part B, AUC(0-inf) of MDZTime frame: Day 1 to Day 4; Day 15 to Day 18
- Part B, AUC(0-inf) of DEXTime frame: Day 1 to Day 4; Day 15 to Day 18
- Part B, AUC(0-inf) of BUPTime frame: Day 4 to Day 8; Day 18 to Day 22
- Part B, AUC(0-inf) of hydroxybupropionTime frame: Day 4 to Day 8; Day 18 to Day 22
- Part B, Cmax of MDZTime frame: Day 1 and Day 15
- Part B, Cmax of DEXTime frame: Day 1 and Day 15
- Part B, Cmax of BUPTime frame: Day 4 and Day 18
- Part B, Cmax of hydroxybupropionTime frame: Day 4 and Day 18
- Part C, AUC(0-t) of ethinyl estradiol (EE)Time frame: Day 1 to Day 5; Day 12 to Day 16
- Part C, AUC(0-t) of norethindrone (NET)Time frame: Day 1 to Day 5; Day 12 to Day 16
- Part C, AUC(0-inf) of EETime frame: Day 1 to Day 5; Day 12 to Day 16
- Part C, AUC(0-inf) of NETTime frame: Day 1 to Day 5; Day 12 to Day 16
- Part C, Cmax of EETime frame: Day 1; Day 12
- Part C, Cmax of NETTime frame: Day 1 and Day 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PPD Austin Clinical Research Unit (CRU)- Phase 1
Austin, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.